Brief: BG Medicine amends license, development agreement with Abbott
12/05/2015 21:36
May 12 (Reuters) - BG Medicine Inc BGMD.O : * On may 8, in anticipation of U.S. launch of abbott' architect galectin-3 assay, co amended license, development agreement with Abbott * Co and Abbott amended agreement due to market dynamic considerations since galectin-3 assay first began development in 2009 * Source text for Eikon ID:nEOL5m3Np3 * Further company coverage BGMD.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on BG Medicine
See all newsBrief: BG Medicine reports Q2 loss of $0.23 per share
Brief: BG Medicine announces proposed underwritten public offering
Brief: BG Medicine announces payoff of secured term loan
Brief: BG Medicine announces one-for-four reverse stock split
Brief: BG Medicine says co's largest customer of BGM galectin test filed for bankruptcy protection